VSTM
$5.67
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule ...
Recent News
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?
The mean of analysts' price targets for Verastem (VSTM) points to a 159.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Verastem (VSTM) Q4 2025 Earnings Call Transcript
Daniel Paterson: Thank you, Julissa. 2025 was a truly transformative year for Verastem as we transition to a commercial stage company following our FDA approval of the first treatment specifically for KRAS-mutated recurrent low-grade serous ovarian cancer, nearly two months ahead of our PDUFA date. Before I continue, I want to address the updated NCCN ovarian cancer guidelines that were released last week and mentioned in our press release today.
Verastem, Inc. Q4 2025 Earnings Call Summary
Moby summary of Verastem, Inc.'s Q4 2025 earnings call
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ...
Verastem Inc (VSTM) reports significant revenue growth and FDA approval, but faces hurdles with NCCN guidelines and financial losses.
Verastem Q4 Earnings Call Highlights
Verastem (NASDAQ:VSTM) executives said the company’s transition to a commercial-stage business accelerated in 2025 following FDA approval of AVMAPKI FAKZYNJA CO-PACK, the first treatment specifically approved for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). On the company’s fourth